Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies.

Authors:
Shin K; Yang J; Yu Y; Son E; Kim K and 1 more

Journal:
Ther Adv Drug Saf

Publication Year: 2022

DOI:
10.1177/20420986221129335

PMCID:
PMC9554114

PMID:
36249084

Journal Information

Full Title: Ther Adv Drug Saf

Abbreviation: Ther Adv Drug Saf

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Medical Research Centre program [grant number NRF-2018 R1A5A2023879], the Basic Science Research Programme [grant number NRF-2020 R1C1C1003741] through a National Research Foundation of Korea grant funded by the Korean government."

Evidence found in paper:

"This meta-analysis was conducted in accordance with PRISMA guidelines. The study protocol is registered with PROSPERO (registration no: CRD42021231789)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025